ImmunityBio (IBRX, Financial) receives a maintained stock rating and price target from analyst Jason Kolbert of D. Boral Capital. The current rating for IBRX remains as "Buy," consistent with the prior rating.
The price target for ImmunityBio (IBRX, Financial) has been maintained at USD 30.00, with no change from the previous target. This assessment by D. Boral Capital highlights continued confidence in the company's valuation.
As of May 28, 2025, the reaffirmed "Buy" rating and stable price target underscore the analyst's positive outlook on ImmunityBio (IBRX, Financial) within the stock market landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for ImmunityBio Inc (IBRX, Financial) is $11.40 with a high estimate of $30.00 and a low estimate of $5.00. The average target implies an upside of 350.59% from the current price of $2.53. More detailed estimate data can be found on the ImmunityBio Inc (IBRX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, ImmunityBio Inc's (IBRX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
